Literature DB >> 21886718

Erythromelalgia accompanying rosuvastatin-associated myopathy.

Nevio Cimolai1, Tomas Cimolai.   

Abstract

BACKGROUND: Secondary erythromelalgia can occur due to various underlying medical disorders or drug toxicity. MAIN OBSERVATIONS: A 75-year old male developed acute secondary erythromelalgia following the onset of rosuvastatin use and associated myopathy. The illness was reversible after discontinuation of the pharmacological agent.
CONCLUSION: Secondary erythromelalgia may occur after rosuvastatin use, but this and other dermatological toxicities are rare.

Entities:  

Keywords:  drug toxicity; erythromelalgia; rosuvastatin; statins

Year:  2009        PMID： 21886718      PMCID： PMC3157787          DOI： 10.3315/jdcr.2009.1026

Source DB:  PubMed          Journal:  J Dermatol Case Rep        ISSN： 1898-7249


  18 in total

1.  UV-B phototoxic effects induced by atorvastatin.

Authors:  Marie-Claude Marguery; Nadia Chouini-Lalanne; Charlotte Drugeon; Agnés Gadroy; Paule Bayle; Fabiènne Journe; Jacques Bazex; Michel D'Incan
Journal:  Arch Dermatol       Date:  2006-08

2.  Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.

Authors:  Lawrence A Leiter; Robert S Rosenson; Evan Stein; John P D Reckless; Karl-Ludwig Schulte; Margo Schleman; Paul Miller; Michael Palmer; Froukje Sosef
Journal:  Atherosclerosis       Date:  2007-01-16       Impact factor: 5.162

3.  Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.

Authors:  Rachna Kasliwal; Lynda V Wilton; Victoria Cornelius; Beate Aurich-Barrera; Saad A W Shakir
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 4.  [Vascular emergencies in dermatology].

Authors:  B Kahle
Journal:  Hautarzt       Date:  2006-03       Impact factor: 0.751

5.  Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study.

Authors:  W G Goettsch; E M Heintjes; J J P Kastelein; T J Rabelink; Saga Johansson; R M C Herings
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-07       Impact factor: 2.890

6.  Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial.

Authors:  Keith C Ferdinand; Luther T Clark; Karol E Watson; Ryan C Neal; Clinton D Brown; B Waine Kong; Boisey O Barnes; William R Cox; Franklin J Zieve; Jonathan Isaacsohn; Joseph Ycas; Philip T Sager; Alex Gold
Journal:  Am J Cardiol       Date:  2005-11-28       Impact factor: 2.778

7.  Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients.

Authors:  Connie B Newman; Gary Palmer; Halit Silbershatz; Michael Szarek
Journal:  Am J Cardiol       Date:  2003-09-15       Impact factor: 2.778

Review 8.  Erythromelalgia.

Authors:  Suzana Ljubojević; Jasna Lipozencić; Nives Pustisek
Journal:  Acta Dermatovenerol Croat       Date:  2004       Impact factor: 1.256

Review 9.  An overview of the extra-lipid effects of rosuvastatin.

Authors:  Michael S Kostapanos; Haralampos J Milionis; Moses S Elisaf
Journal:  J Cardiovasc Pharmacol Ther       Date:  2008-05-06       Impact factor: 2.457

10.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

Authors:  Luigi Tavazzi; Aldo P Maggioni; Roberto Marchioli; Simona Barlera; Maria Grazia Franzosi; Roberto Latini; Donata Lucci; Gian Luigi Nicolosi; Maurizio Porcu; Gianni Tognoni
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321
View more
  3 in total

1.  A generalised sensation of coldness following introduction of rosuvastatin therapy.

Authors:  Niem Tu Huynh; Philippe Huot
Journal:  BMJ Case Rep       Date:  2014-10-09

Review 2.  Erythromelalgia: a cutaneous manifestation of neuropathy?

Authors:  María Bibiana Leroux
Journal:  An Bras Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.896

Review 3.  Current pain management strategies for patients with erythromelalgia: a critical review.

Authors:  See Wan Tham; Marian Giles
Journal:  J Pain Res       Date:  2018-08-30       Impact factor: 3.133
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.